Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Mesenchymal Stromal Cells: From Clinical Safety and Efficiency to Therapeutic...
share announcement

Mesenchymal Stromal Cells: From Clinical Safety and Efficiency to Therapeutic Use

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Immunology".

Deadline for manuscript submissions: closed (28 February 2021) | Viewed by 1995

Special Issue Editor

Dr. Guido Moll

E-Mail Website
Guest Editor
BCRT – Berlin Institute of Health (BIH) Center for Regenerative Therapies at theCharité University Medicine Berlin, Berlin, Germany

Special Issue Information

Dear Colleagues,

For more than thirty years, products of mesenchymal stromal/stem cells (MSCs) have been studied as novel therapeutic agents, to close a crucial gap in modern medicine: To overcome debilitating disease/pathology by restoring homeostasis and regenerating/repairing affected tissues and organs instead of merely treating symptoms, but not the underlying cause. Due to their multifaceted immunomodulatory and regenerative properties, MSCs have been identified as crucial mediators to fulfill this great clinical need. While early studies have mainly focussed on cells derived from bone marrow, the field has largely diversified over the past decade, now including cell products from many different vascularized tissue sources, e.g., adipose tissue and perinatal tissue sources, such as placenta and umbilical cord. As with any other novel therapeutic agent, clinical safety, efficacy, and also the underlying mechanism of action have to be proven for any new treatment indication. The optimal manufacturing, delivery, and monitoring of MSC therapeutics to optimize clinical outcomes and develop sustainable products is a crucial aspect. We welcome submissions from researchers who wish to share their novel findings on clinical studies of MSCs in multiple treatment indications (e.g., Coronavirus-induced disease 2019 - COVID-19).

Dr. Guido Moll
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Mesenchymal stromal/stem cells (MSCs)
  • Regenerative medicine
  • Immunomodulation

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

20 pages, 5020 KiB  
Article
The Effect of Proinflammatory Cytokines on the Proliferation, Migration and Secretory Activity of Mesenchymal Stem/Stromal Cells (WJ-MSCs) under 5% O2 and 21% O2 Culture Conditions
by Aleksandra Wedzinska, Anna Figiel-Dabrowska, Hanna Kozlowska and Anna Sarnowska
J. Clin. Med. 2021, 10(9), 1813; https://doi.org/10.3390/jcm10091813 - 21 Apr 2021
Cited by 10 | Viewed by 1741
Abstract
Treatment with Mesenchymal Stem/Stromal Cells (MSCs) in clinical trials is becoming one of the most-popular and fast-developing branches of modern regenerative medicine, as it is still in an experimental phase. The cross-section of diseases to which these cells are applied is very wide, [...] Read more.
Treatment with Mesenchymal Stem/Stromal Cells (MSCs) in clinical trials is becoming one of the most-popular and fast-developing branches of modern regenerative medicine, as it is still in an experimental phase. The cross-section of diseases to which these cells are applied is very wide, ranging from degenerative diseases, through autoimmune processes and to acute inflammatory diseases, e.g., viral infections. Indeed, now that first clinical trials applying MSCs against COVID-19 have started, important questions concern not only the therapeutic properties of MSCs, but also the changes that might occur in the cell features as a response to the “cytokine storm” present in the acute phase of an infection and capable of posing a risk to a patient. The aim of our study was thus to assess changes potentially occurring in the biology of MSCs in the active inflammatory environment, e.g., in regards to the cell cycle, cell migration and secretory capacity. The study using MSCs derived from Wharton’s jelly (WJ-MSCs) was conducted under two aerobic conditions: 21% O2 vs. 5% O2, since oxygen concentration is one of the key factors in inflammation. Under both oxygen conditions cells were exposed to proinflammatory cytokines involved significantly in acute inflammation, i.e., IFNγ, TNFα and IL-1β at different concentrations. Regardless of the aerobic conditions, WJ-MSCs in the inflammatory environment do not lose features typical for mesenchymal cells, and their proliferation dynamic remains unchanged. Sudden fluctuations in proliferation, the early indicator of potential genetic disturbance, were not observed, while the cells’ migration activity increased. The presence of pro-inflammatory factors was also found to increase the secretion of such anti-inflammatory cytokines as IL-4 and IL-10. It is concluded that the inflammatory milieu in vitro does not cause phenotype changes or give rise to proliferation disruption of WJ-MSCs, and nor does it inhibit the secretory properties providing for their use against acute inflammation. Full article
(This article belongs to the Special Issue Mesenchymal Stromal Cells: From Clinical Safety and Efficiency to Therapeutic Use)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop